Compare Danaher Corporation (DHR) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs TORM plc — how do they compare? Danaher Corporation trades at $218.41 (market cap $152.87B), while TORM plc trades at $40.22 (market cap $4.12B). The key difference: Danaher Corporation is far larger — about 37.1× TORM plc's market cap, and TORM plc pays the higher dividend (11.03%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and TORM plc for 23 Days on average.
| DHR | TRMD | |
|---|---|---|
Market Cap | $152.87B | $4.12B |
Volume | 5,228,698 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $242.05 | $41.05 |
52-Week Low | $161.91 | $19.39 |
Typical Hold Time | 69 Days | 23 Days |
Enterprise Value | $175.08B | $4.83B |
Dividend Yield | 0.74% | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
TRMD trades at $38.92, down 0.33% on the day, with strong technical momentum showing a bullish moving average signal despite RSI_6 indicating potential overbought conditions. Fundamentally, the company demonstrates robust profitability with 35.52% net income margin and attractive valuation metrics including a 6.59 P/E ratio. Recent earnings showed mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates.
The outlook remains positive with 100% analyst buy ratings and improving cash flow projections for 2026. Key risks include spot rate volatility in the tanker market and recent insider selling activity. The stock offers value characteristics with strong dividend potential but faces near-term headwinds from declining contracted rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
